0000000000472238

AUTHOR

Aikaterini Papagianni

showing 2 related works from this author

The switch from proteasome to immunoproteasome is increased in circulating cells of patients with fast progressive immunoglobulin A nephropathy and a…

2021

  The proteasome to immunoproteasome (iPS) switch consists of β1, β2 and β5 subunit replacement by low molecular weight protein 2 (LMP2), LMP7 and multicatalytic endopeptidase-like complex-1 (MECL1) subunits, resulting in a more efficient peptide preparation for major histocompatibility complex 1 (MHC-I) presentation. It is activated by toll-like receptor (TLR) agonists and interferons and may also be influenced by genetic variation. In a previous study we found an iPS upregulation in peripheral cells of patients with immunoglobulin A nephropathy (IgAN). We aimed to investigate in 157 IgAN patients enrolled through the multinational Validation Study of the Oxford Classification of IgAN (VAL…

0301 basic medicinemedicine.medical_specialtyProteasome Endopeptidase Complex030232 urology & nephrologyCD46; IgA nephropathy; biomarkers; complement; immune proteasome; progression; risk factorsMajor histocompatibility complexMembrane Cofactor Protein03 medical and health sciences0302 clinical medicineDownregulation and upregulationInternal medicinemedicinerisk factorsHumanscomplementRNA MessengerReceptorCD46Transplantationmedicine.diagnostic_testbiologybusiness.industrybiomarkersPSMB8Glomerulonephritis IGAIgA nephropathyPSMB9medicine.diseaseUp-RegulationTLR2030104 developmental biologyEndocrinologyNephrologybiology.proteinprogressionRenal biopsyimmune proteasomebusinessKidney diseaseGenome-Wide Association StudyNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
researchProduct

A randomized multicenter trial on a lung ultrasound-guided treatment strategy in patients on chronic hemodialysis with high cardiovascular risk

2021

Lung congestion is a risk factor for all-cause and cardiovascular mortality in patients on chronic hemodialysis, and its estimation by ultrasound may be useful to guide ultrafiltration and drug therapy in this population. In an international, multi-center randomized controlled trial (NCT02310061) we investigated whether a lung ultrasound-guided treatment strategy improved a composite end point (all-cause death, non-fatal myocardial infarction, decompensated heart failure) vs usual care in patients receiving chronic hemodialysis with high cardiovascular risk. Patient-Reported Outcomes (Depression and the Standard Form 36 Quality of Life Questionnaire, SF36) were assessed as secondary outcome…

cardiovascular riskmedicine.medical_specialtymedicine.medical_treatmentPopulationlung congestionlaw.inventionKidney FailureRandomized controlled trialRenal DialysisRisk FactorslawMulticenter trialInternal medicineHumansMedicineChronicRisk factorESRDeducationLungUltrasonography InterventionalDialysisUltrasonographylung ultrasoundeducation.field_of_studyInterventionalbusiness.industryHazard ratiochronic kidney failuremedicine.diseaseESRD; cardiovascular risk; chronic kidney failure; heart failure hemodialysis; lung congestion; lung ultrasoundHeart Disease Risk FactorsCardiovascular DiseasesNephrologyHeart failureQuality of LifeKidney Failure ChronicHemodialysisheart failure hemodialysisbusinessKidney international
researchProduct